Debate: Targeted therapy for RAS/BRAF WT left sided colon cancers - EGFR antibodies are mandatory
Vložit
- čas přidán 9. 09. 2024
- In this presentation from the 2017 Great Debates & Updates in GI Malignancies, Dr. Eric Van Cutsem argues that EGFR antibodies are mandatory targeted therapy for RAS/BRAF wild-type left sided colon cancers.
Earn CME Credit for a related activity: elc.imedex.com/...
© 2017 Imedex, LLC.